journal article·2024-06Open access

Dual Activity of Type III PI3K Kinase Vps34 is Critical for NK Cell Development and Senescence

Shasha Chen, Zehua Li, Jin Feng, Yuhe Quan, Junming He, Jiqing Hao, Zhongjun Dong

Advanced Science· Volume 11· Issue 21

Abstract

Abstract Vps34 is the unique member of the class III phosphoinositide 3‐kinase family that performs both vesicular transport and autophagy. Its role in natural killer (NK) cells remains uncertain. In this study, a model without Vps34 (Vps34fl/fl/CD122Cre/+) is generated, deleting Vps34 during and after NK‐cell commitment. These mice exhibit a nearly 90% decrease in NK cell count and impaired differentiation. A mechanistic study reveals that the absence of Vps34 disrupts the transport of IL‐15 receptor subunit alpha CD122 to the cell membrane, resulting in reduced responsiveness of NK cells to IL‐15. In mice lacking Vps34 at the terminal stage of NK‐cell development (Vps34fl/fl/Ncr1Cre/+), NK cells gradually diminish during aging. This phenotype is associated with autophagy deficiency and the stress induced by reactive oxygen species (ROS). Therefore, terminally differentiated NK cells lacking Vps34 display an accelerated senescence phenotype, while the application of antioxidants effectively reverses the senescence caused by Vps34 deletion by neutralizing ROS. In summary, this study unveils the dual and unique activity of Vps34 in NK cells. Vps34‐mediated vesicular transport is crucial for CD122 membrane trafficking during NK cell commitment, whereas Vps34‐mediated autophagy can delay NK cell senescence.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune Cell Function and Interaction · Autophagy in Disease and Therapy · Polyamine Metabolism and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Allergy The First Affiliated Hospital of Anhui Medical University and Institute of Clinical Immunology Anhui Medical University Hefei 230032 China

Innovative Institute of Tumor Immunity and Medicine (ITIM) Hefei 230032 China

Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy Hefei 230032 China

Inflammation and Immune Mediated Diseases Laboratory of Anhui Province Anhui Medical University Hefei 230032 China

State Key Laboratory of Membrane Biology School of Medicine and Institute for Immunology Tsinghua University Beijing 100084 China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Anhui Provincial Department of Education

References (52)

Show source-provided references
1. 10.1038/740310.1038/7403 ↗
2. 10.1146/annurev.immunol.17.1.18910.1146/annurev.immunol.17.1.189 ↗
3. 10.1146/annurev.immunol.24.021605.09072710.1146/annurev.immunol.24.021605.090727 ↗
4. 10.1084/jem.191.5.77110.1084/jem.191.5.771 ↗
5. 10.1016/S1074-7613(00)80664-010.1016/S1074-7613(00)80664-0 ↗
6. 10.1038/nri190110.1038/nri1901 ↗
7. 10.1016/S1074-7613(02)00429-610.1016/S1074-7613(02)00429-6 ↗
8. 10.1038/nrm288210.1038/nrm2882 ↗
9. 10.1146/annurev-immunol-032712-09594610.1146/annurev-immunol-032712-095946 ↗
10. 10.1038/nri105610.1038/nri1056 ↗
11. 10.1126/science.283.5400.39310.1126/science.283.5400.393 ↗
12. 10.1182/blood-2007-02-07536610.1182/blood-2007-02-075366 ↗
13. 10.1007/s10875-014-0012-910.1007/s10875-014-0012-9 ↗
14. 10.1172/JCI7719810.1172/JCI77198 ↗
15. 10.1084/jem.2014170310.1084/jem.20141703 ↗
16. 10.1038/nrm270810.1038/nrm2708 ↗
17. 10.1038/ncb308910.1038/ncb3089 ↗
18. 10.1016/j.cell.2012.12.01610.1016/j.cell.2012.12.016 ↗
19. 10.1038/ncb275710.1038/ncb2757 ↗
20. 10.4049/jimmunol.110071010.4049/jimmunol.1100710 ↗
21. 10.1080/15548627.2020.175297910.1080/15548627.2020.1752979 ↗
22. 10.1038/nature1618710.1038/nature16187 ↗
23. 10.1038/nature2138810.1038/nature21388 ↗
24. 10.1038/nature0472310.1038/nature04723 ↗
25. 10.1038/nature0797610.1038/nature07976 ↗
26. 10.1126/science.108778210.1126/science.1087782 ↗
27. 10.1038/ncomms1102310.1038/ncomms11023 ↗
28. 10.1007/s12026-007-8006-910.1007/s12026-007-8006-9 ↗
29. 10.1016/j.it.2013.07.00510.1016/j.it.2013.07.005 ↗
30. 10.1038/ni.293610.1038/ni.2936 ↗
31. 10.1038/ncomms1273010.1038/ncomms12730 ↗
32. 10.4049/jimmunol.167.9.501110.4049/jimmunol.167.9.5011 ↗
33. 10.1007/s11357-009-9100-910.1007/s11357-009-9100-9 ↗
34. 10.1136/annrheumdis-2013-20388110.1136/annrheumdis-2013-203881 ↗
35. 10.1038/ni.293610.1038/ni.2936 ↗
36. 10.1038/nature1060010.1038/nature10600 ↗
37. 10.1038/nature1693210.1038/nature16932 ↗
38. 10.1073/pnas.92.20.936310.1073/pnas.92.20.9363 ↗
39. 10.1038/nprot.2009.19110.1038/nprot.2009.191 ↗
40. 10.1189/jlb.091243810.1189/jlb.0912438 ↗
41. 10.1182/blood-2010-06-29163310.1182/blood-2010-06-291633 ↗
42. 10.1073/pnas.111206410810.1073/pnas.1112064108 ↗
43. 10.1038/ni.178710.1038/ni.1787 ↗
44. 10.1084/jem.2013239810.1084/jem.20132398 ↗
45. 10.1084/jem.2009217610.1084/jem.20092176 ↗
46. 10.1084/jem.2013041710.1084/jem.20130417 ↗
47. 10.1093/intimm/dxm12010.1093/intimm/dxm120 ↗
48. 10.1074/jbc.M111.30693610.1074/jbc.M111.306936 ↗
49. 10.1038/nature0845510.1038/nature08455 ↗
50. 10.1038/ncomms500410.1038/ncomms5004 ↗
51. 10.1038/ncb325610.1038/ncb3256 ↗
52. 10.4049/jimmunol.130162510.4049/jimmunol.1301625 ↗